

<u>Korlym</u>							
Patient Infor	mation:						
Name:							
Member ID:							
Address:							
City, State, Z	ip:						
Date of Birth:							
Prescriber lı	nformation:						
Name:							
NPI:							
Phone Numb	er.						
Fax Number							
Address:							
City, State, Z	ip:						
Oity, Otato, 2							
Requested I	Medication						
Rx Name:							
Rx Strength							
Rx Quantity:							
Rx Frequency:							
Rx Route of							
Administration:							
Diagnosis and ICD Code:							
orescribed a m quantities can b Upon receipt	edication for your be provided. Plea of the completed	fit requires that we review certain requests for coverage with the pre- patient that requires Prior Authorization before benefit coverage or cov- se complete the following questions then fax this form to the toll-free nu- form, prescription benefit coverage will be determined based on te that supporting clinical documentation is required	rerage of a common of the plant	additiona ed below n's rules			
		sis or indication? hing's syndrome (If checked, go to 2)					
'	ype 2 diabetes r cked, no further	ot associated with endogenous Cushing's syndrome (If questions)					
[] P	sychotic feature	s of psychotic depression (If checked, no further questions)					
[] A	ll other indication	ns or diagnoses (If checked, no further questions)					
2 Is the		er than or equal to 18 year(s) of age? If yes, please specify	Yes	No			

			i
	[If no, no further questions.]		
3	Has the requested medication been prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of Cushing's syndrome? [If no, no further questions.]	Yes	No
4	Will the requested medication be used along with long term systemic steroids? [If yes, no further questions.]	Yes	No
5	Is the patient currently receiving the requested medication? [If no, skip to question 15.]	Yes	No
6	Has the patient been receiving medication samples for the requested medication? [If yes, skip to question 15.]	Yes	No
7	Does the patient have a previously approved prior authorization (PA) on file with	Yes	No
	the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 14.]		
8	Has documentation been provided to confirm that the patient's condition has improved or stabilized based upon the prescriber's assessment while on therapy? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
9	Has the patient's glycemic control (HbA1c) improved compared to baseline? [If no, no further questions.]	Yes	No
10	Has the patient been adherent to the requested medication? [If no, no further questions.]	Yes	No
11	Is the patient a male or female? [] Male (If checked, no further questions)		
	[] Female (If checked, go to 12)		
12	Is the patient a woman of reproductive potential? [If no, no further questions.]	Yes	No
13	Has documentation been provided to confirm that the patient has a non-hormonal contraception plan? ACTION REQUIRED: Submit supporting documentation. [No further questions]	Yes	No
14	Does the provider have a documented clinical response of the member's condition which has stabilized or improved based upon the prescriber's assessment?	Yes	No

	ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]		
15	Is the patient a male or female? [] Male (If checked, go to 20)		
	[] Female (If checked, go to 16)		
16	Is the patient a woman of reproductive potential? [If no, skip to question 19.]	Yes	No
17	Has documentation been provided to confirm that the patient has a non-hormonal contraception plan? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
18	Has documentation been provided to confirm that the patient has negative pregnancy test prior to initiating therapy? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
19	Will the requested medication be used in patients with a history of unexplained vaginal bleeding, endometrial hyperplasia with atypia or endometrial carcinoma? [If yes, no further questions.]	Yes	No
20	Is the patient awaiting therapeutic response after radiotherapy? [If no, skip to question 22.]	Yes	No
21	Has the patient undergone radiotherapy for treatment of endogenous Cushing's syndrome within the last 24 months? [If yes, skip to question 23.] [If no, no further questions.]	Yes	No
22	According to the prescriber, is the patient a candidate for surgery or has surgery been curative? [If yes, no further questions.]	Yes	No
23	Has documentation been provided to confirm the requested medication is used to treat high blood sugar (hyperglycemia) caused by high cortisol levels in the blood (hypercortisolism) in patients who have type 2 diabetes mellitus or glucose intolerance? ACTION REQUIRED: Submit supporting documentation. [NOTE: Documentation of glucose intolerance must be assessed by a 2 hour glucose tolerance test with plasma glucose value of 140 - 199 mg/dL, fasting serum glucose test, or HbA1c.] [If no, no further questions.]	Yes	No
24	Has documentation been provided to confirm that the patient has had intolerance, contraindication to or failed treatment with both insulin and metformin therapy or with at least two other oral diabetic therapies? ACTION REQUIRED: Submit	Yes	No



supporting documentation. [If no, no further questions.]

Will the patient's drug regimen be assessed for any drug interactions or contraindications such as concurrent use with lovastatin, simvastatin, cyclosporine, fentanyl, tacrolimus, etc.?

Yes No

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.